Torchmark (TMK) Reaches $81.41 High on Oct, 12; MARINA BIOTECH (MRNA) Shorts Increased By 201.47%

October 12, 2017 - By Marguerite Chambers

The stock of Torchmark Corporation (NYSE:TMK) reached all time high today, Oct, 12 and still has $88.74 target or 9.00% above today’s $81.41 share price. This indicates more upside for the $9.52B company. This technical setup was reported by If the $88.74 PT is reached, the company will be worth $856.80 million more. About 86,957 shares traded. Torchmark Corporation (NYSE:TMK) has risen 25.88% since October 12, 2016 and is uptrending. It has outperformed by 9.18% the S&P500.

MARINA BIOTECH INCORPORATED (OTCMKTS:MRNA) had an increase of 201.47% in short interest. MRNA’s SI was 20,500 shares in October as released by FINRA. Its up 201.47% from 6,800 shares previously. With 7,100 avg volume, 3 days are for MARINA BIOTECH INCORPORATED (OTCMKTS:MRNA)’s short sellers to cover MRNA’s short positions. It is 0.00% or $0 reaching $2.22 per share. It is up 0.00% since October 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 0.89 in Q2 2017. Its up 0.07, from 0.82 in 2017Q1. It improved, as 15 investors sold Torchmark Corporation shares while 159 reduced holdings. 49 funds opened positions while 105 raised stakes. 80.55 million shares or 3.85% less from 83.78 million shares in 2017Q1 were reported. Clifford Swan Invest Counsel Lc holds 0.01% in Torchmark Corporation (NYSE:TMK) or 2,690 shares. Shell Asset Mgmt invested in 0.06% or 30,392 shares. North Carolina-based Bank Of America De has invested 0.01% in Torchmark Corporation (NYSE:TMK). Sei Invests Company holds 0.01% or 44,906 shares. Advisor Prtnrs Limited Liability Co invested 0.09% in Torchmark Corporation (NYSE:TMK). Texas Permanent School Fund holds 0.03% of its portfolio in Torchmark Corporation (NYSE:TMK) for 30,568 shares. Origin Asset Mngmt Llp reported 135,725 shares or 0.64% of all its holdings. Ohio-based Victory has invested 0.09% in Torchmark Corporation (NYSE:TMK). Moreover, Captrust Fincl has 0% invested in Torchmark Corporation (NYSE:TMK). The Quebec – Canada-based Caisse De Depot Et Placement Du Quebec has invested 0.38% in Torchmark Corporation (NYSE:TMK). Moreover, Sandy Spring Commercial Bank has 0% invested in Torchmark Corporation (NYSE:TMK). Brown Advisory Incorporated has invested 0% of its portfolio in Torchmark Corporation (NYSE:TMK). Amp Capital Investors Limited holds 0.03% or 61,490 shares in its portfolio. Hillsdale Investment holds 0% of its portfolio in Torchmark Corporation (NYSE:TMK) for 160 shares. Eulav Asset Mgmt holds 0.09% or 23,900 shares in its portfolio.

Torchmark Corporation is an insurance holding company. The company has market cap of $9.52 billion. The Company, through its subsidiaries, provides a range of life and health insurance products and annuities to a base of customers. It has a 18.05 P/E ratio. The Company’s divisions include life insurance, health insurance, annuities and investment.

Since May 30, 2017, it had 1 buying transaction, and 1 sale for $149,662 activity. Another trade for 2,500 shares valued at $188,200 was bought by NEWTON LLOYD W. DICHIARO STEVEN JOHN also sold $337,862 worth of Torchmark Corporation (NYSE:TMK) on Wednesday, May 31.

Analysts await Torchmark Corporation (NYSE:TMK) to report earnings on October, 24. They expect $1.20 EPS, up 4.35% or $0.05 from last year’s $1.15 per share. TMK’s profit will be $140.33 million for 16.96 P/E if the $1.20 EPS becomes a reality. After $1.19 actual EPS reported by Torchmark Corporation for the previous quarter, Wall Street now forecasts 0.84% EPS growth.

Among 10 analysts covering Torchmark Corporation (NYSE:TMK), 0 have Buy rating, 4 Sell and 6 Hold. Therefore 0 are positive. Torchmark Corporation has $78.0 highest and $51 lowest target. $64’s average target is -21.39% below currents $81.41 stock price. Torchmark Corporation had 26 analyst reports since July 29, 2015 according to SRatingsIntel. Wells Fargo upgraded the shares of TMK in report on Wednesday, January 13 to “Outperform” rating. The stock of Torchmark Corporation (NYSE:TMK) earned “Hold” rating by Wood on Monday, April 24. On Wednesday, February 24 the stock rating was downgraded by Goldman Sachs to “Sell”. Bank of America upgraded the shares of TMK in report on Wednesday, June 29 to “Neutral” rating. The stock of Torchmark Corporation (NYSE:TMK) has “Hold” rating given on Friday, May 26 by Keefe Bruyette & Woods. The firm has “Neutral” rating by Goldman Sachs given on Friday, July 15. Wells Fargo maintained Torchmark Corporation (NYSE:TMK) on Wednesday, July 26 with “Sell” rating. Goldman Sachs initiated it with “Neutral” rating and $61.0 target in Tuesday, November 17 report. The firm has “Underperform” rating by Bank of America given on Wednesday, July 29. Wood maintained it with “Hold” rating and $75 target in Monday, May 29 report.

Marina Biotech, Inc. is a biotechnology firm focused on the discovery, development and commercialization of nucleic acid therapies to treat orphan diseases. The company has market cap of $21.84 million. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis , and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It currently has negative earnings. It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By :